Stock Market Reviews

ZLAB (Zai Lab Limited) News

Get the latest news, insights, and market updates on ZLAB (Zai Lab Limited). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
  Asian equities traded in the US as American depositary receipts were headed lower Thursday morning,
  Oct 30, 2025 - $ZLAB
• Zai Lab Says Potential Lung Cancer Treatment Shows High Response Rate in Updated Phase 1 Data
  Zai Lab (ZLAB) said Friday that updated data from a phase 1 study of zocilurtatug pelitecan, or zoci
  Oct 24, 2025 - $ZLAB
• Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
  SHANGHAI & CAMBRIDGE, Mass., October 24, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an oral presentation and was included as part of the press program at the AACR-NCI-EORTC International Con
  Oct 24, 2025 - $ZLAB
• Asian Equities Traded in the US as American Depositary Receipts End Week Higher in Friday Trading
  Asian equities traded in the US as American depositary receipts were trending higher Friday morning,
  Oct 24, 2025 - $ZLAB
• Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
  SHANGHAI & CAMBRIDGE, Mass., October 15, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
  Oct 15, 2025 - $ZLAB
• A Look at Zai Lab (NasdaqGM:ZLAB) Valuation Following Key Clinical Progress and New Data Announcement
  Zai Lab (NasdaqGM:ZLAB) is making moves that investors have been watching closely, as it announced that new data from its Phase 1 trial of zocilurtatug pelitecan will be spotlighted at an upcoming international oncology conference. The company’s plans to initiate a Phase 3 registrational trial by year-end and host an investor update also set the stage for updates on its clinical pipeline. See our latest analysis for Zai Lab. While Zai Lab’s latest announcements about its oncology pipeline...
  Oct 15, 2025 - $ZLAB
• Could Zai Lab’s (ZLAB) Pipeline Milestone Reveal Shifting Dynamics in Its Oncology Growth Narrative?
  Zai Lab Limited announced that new data from its global Phase 1 trial of zocilurtatug pelitecan (ZL-1310), a DLL3-targeted therapy for extensive-stage small cell lung cancer, was selected for an oral presentation at a major oncology conference in October 2025, with a Phase 3 trial planned by year-end. This recognition highlights pipeline progress and raises the profile of an emerging asset that could broaden Zai Lab's oncology portfolio in a highly competitive market. We'll look at how the...
  Oct 15, 2025 - $ZLAB
• Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
  SHANGHAI & CAMBRIDGE, Mass., October 13, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, Massachusetts. The presentation will
  Oct 13, 2025 - $ZLAB
• Zai Lab Limited (ZLAB): A Bull Case Theory
  We came across a bullish thesis on Zai Lab Limited on Value investing subreddit by mrmrmrj. In this article, we will summarize the bulls’ thesis on ZLAB. Zai Lab Limited’s share was trading at $30.00 as of September 4th. Zai Lab (ZLAB), a $3.3B market cap Chinese pharmaceutical company, is growing revenues at 40%+ and positioned to […]
  Sep 16, 2025 - $ZLAB
• Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
  Asian equities traded in the US as American depositary receipts were tracking higher Wednesday morni
  Sep 10, 2025 - $ZLAB